Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00125944 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

A Phase 3 study of Healthy and Influenza, sponsored by MedImmune.

Completed
Registry status
Phase 3
Development phase
300
Enrollment target
4
Study locations

NCT00125944: Completed Phase 3 study of Healthy and Influenza, sponsored by MedImmune.

NCT00125944 is a Phase 3 study of Healthy and Influenza that has completed, run by MedImmune. The registered enrollment target is 300 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (54% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00125944, a Phase 3 study of Healthy and Influenza, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 3
Development phase
300 participants
Enrollment target
4
Study locations

Study Summary

The objective is to assess the safety of bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.

Conditions Studied

Interventions

  • BIOLOGICAL FluMist

Study Locations (4)

California

  • Radiant Research, San Diego - San Diego

Florida

  • Radiant Research, Daytona Beach - Daytona Beach

Oregon

  • Radiant Research - Portland

Texas

  • Healthcare Discoveries, Inc. - San Antonio

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2005-07
Est. Completion 2006-01
Phase Phase 3
MedImmune

210 total trials

What the finished NCT00125944 record still lists

NCT00125944 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (54% lower).

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which FluMist is the first listed.

NCT00125944 reports a single indexed study location in California, Florida, Oregon.

Frequently Asked Questions

What is clinical trial NCT00125944 about?

NCT00125944 is a clinical study titled "Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults". The objective is to assess the safety of bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.

What is the current status of trial NCT00125944?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2005-07. Estimated completion is 2006-01.

What conditions does trial NCT00125944 study?

This clinical trial studies the following conditions: Healthy, Influenza.

What interventions are being tested in trial NCT00125944?

The interventions under investigation include: FluMist (BIOLOGICAL).

Who is sponsoring clinical trial NCT00125944?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00125944 being conducted?

This trial has 4 study locations across California, Florida, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00125944's enrollment target sits among peer trials

300 77th of 1090 higher than 1,004 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00125944, the US trial registry maintained by the National Library of Medicine. NCT00125944 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.